Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feb. 15, Vol. 32, No. 4

    • Point of View

      • How Is the FDA Really Doing?
      • Henry I. Miller, M.D.
      • I read with interest—and mounting skepticism—Patricia Dimond’s Insight & Intelligence™ piece about FDA, “FDA New Drug Approvals in 2011 Outpace Recent Past,” on GEN’s website. Some of its assertions and assumptions lacked essential context and d ... more »
    • Feature Articles

      • Aiming to Optimize qPCR Steps
      • Michael D. O'Neil
      • Progress in real-time quantitative PCR (qPCR) technology has been steady since its invention approximately 15 years ago. Recent innovations and where the technology is headed in the future will be discussed at a Select Biosciences’ upcoming conferen ... more »
      • Bioinstrument Manufacturers Go Global
      • John Sterling
      • During President Obama’s State of the Union speech last month, he called for revitalizing the U.S. manufacturing industry: “We have a huge opportunity, at this moment, to bring manufacturing back,” he said. “But we have to seize it. Tonight, my me ... more »
      • Coupling SPR Increases Value
      • Kathy Liszewski
      • Surface plasmon resonance (SPR) is not the new kid on the block. It’s been an industry workhorse technology for more than 20 years. What is new is coupling this premier technology with thermodynamic methodologies or molecular dynamics simulations. W ... more »
      • Getting the Most from Outsourced Projects
      • Gail Dutton
      • Making outsourcing an efficient and effective option for biotechnology manufacturing often is dependent upon innovation, a keen awareness of potential risks, and close collaborative relationships between CMOs and their clients. Recipharm Pharmaceuti ... more »
    • Tutorials

      • Finding New, High-Quality Compounds
      • Matthew Segall
      • One of the defining challenges of drug discovery is the need to make complex decisions regarding the design and selection of potential drug molecules based on a relative scarcity of experimental data. Synthesizing compounds and generating experiment ... more »
    • Corporate Profile

      • Firm Focuses Operations on Gene Silencing
      • Carol Potera
      • Benitec, an Australian biotechnology company, holds a predominant patent position for silencing genes with DNA-directed RNA interference (ddRNAi). It is developing therapeutics to prove the validity of ddRNAi in treating cancer, infectious diseases, ... more »
    • BioMarket Trends

    • Company Updates

      • Protein Production Services Come Stateside
      • Novoprotein Scientific was among the early contract manufacturers of recombinant proteins, according to Huaxing Zhu, Ph.D., president and CEO. Dr. Zhu started Novoprotein in 2004 when he saw a growing demand for protein expression, purification, and ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »